Vita Life Sciences Ltd
ASX:VLS

Watchlist Manager
Vita Life Sciences Ltd Logo
Vita Life Sciences Ltd
ASX:VLS
Watchlist
Price: 1.915 AUD Market Closed
Market Cap: 107.3m AUD
Have any thoughts about
Vita Life Sciences Ltd?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

6.6
Current
7.3
Median
13.7
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
6.6
=
Enterprise Value
80.4m AUD
/
EBITDA
12.2m AUD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
AU
Vita Life Sciences Ltd
ASX:VLS
Average EV/EBITDA: 414.4
6.6
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48
42%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
20.3
22%
0.9
US
Johnson & Johnson
NYSE:JNJ
11.3
4%
2.8
US
Merck & Co Inc
NYSE:MRK
10.5
63%
0.2
CH
Roche Holding AG
SIX:ROG
10.6
7%
1.5
UK
AstraZeneca PLC
LSE:AZN
169.8
18%
9.4
CH
Novartis AG
SIX:NOVN
9.7
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.6
9%
1.2

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A